{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:03:40Z","timestamp":1777518220633,"version":"3.51.4"},"reference-count":166,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>Disease-modifying therapies (DMT) for Alzheimer\u2019s disease (AD) are highly longed-for. In this quest, anti-amyloid therapies take center stage supported by genetic facts that highlight an imbalance between production and clearance of amyloid-\u03b2 peptide (A\u03b2) in AD patients. Indeed, evidence from basic research, human genetic and biomarker studies, suggests the accumulation of A\u03b2 as a driver of AD pathogenesis and progression. The aspartic protease \u03b2-site A\u03b2PP cleaving enzyme (BACE1) is the initiator for A\u03b2 production. Underpinning a critical role for BACE1 in AD pathophysiology are the elevated BACE1 concentration and activity observed in the brain and body fluids of AD patients. Therefore, BACE1 is a prime drug target for reducing A\u03b2 levels in early AD. Small-molecule BACE1 inhibitors have been extensively developed for the last 20 years. However, clinical trials with these molecules have been discontinued for futility or safety reasons. Most of the observed adverse side effects were due to other aspartic proteases cross-inhibition, including the homologue BACE2, and to mechanism-based toxicity since BACE1 has substrates with important roles for synaptic plasticity and synaptic homeostasis besides amyloid-\u03b2 protein precursor (A\u03b2PP). Despite these setbacks, BACE1 persists as a well-validated therapeutic target for which a specific inhibitor with high substrate selectivity may yet to be found. In this review we provide an overview of the evolution in BACE1 inhibitors design pinpointing the molecules that reached advanced phases of clinical trials and the liabilities that precluded adequate trial effects. Finally, we ponder on the challenges that anti-amyloid therapies must overcome to achieve clinical success.<\/jats:p>","DOI":"10.3233\/jad-240146","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:43:03Z","timestamp":1719315783000},"page":"S53-S78","source":"Crossref","is-referenced-by-count":29,"title":["BACE1 Inhibitors for Alzheimer\u2019s Disease: Current Challenges and Future Perspectives"],"prefix":"10.1177","volume":"101","author":[{"given":"Judite R.M.","family":"Coimbra","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"},{"name":"Center for Innovative Biomedicine and Biotechnology (CIBB), Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal"}]},{"given":"Rosa","family":"Resende","sequence":"additional","affiliation":[{"name":"Center for Innovative Biomedicine and Biotechnology (CIBB), Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal"},{"name":"Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal"}]},{"given":"Jos\u00e9 B.A.","family":"Cust\u00f3dio","sequence":"additional","affiliation":[{"name":"Center for Innovative Biomedicine and Biotechnology (CIBB), Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal"},{"name":"Laboratory of Biochemistry and Biology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-6083","authenticated-orcid":false,"given":"Jorge A.R.","family":"Salvador","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"},{"name":"Center for Innovative Biomedicine and Biotechnology (CIBB), Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-2481","authenticated-orcid":false,"given":"Armanda E.","family":"Santos","sequence":"additional","affiliation":[{"name":"Center for Innovative Biomedicine and Biotechnology (CIBB), Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal"},{"name":"Laboratory of Biochemistry and Biology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-240146_ref1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: An update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.3233\/JAD-240146_ref2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.3233\/JAD-240146_ref3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-240146_ref4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: Challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.3233\/JAD-240146_ref5","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from A\u03b21-42 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-240146_ref6","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.freeradbiomed.2008.03.012","article-title":"Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease","volume":"44","author":"Resende","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.3233\/JAD-240146_ref7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1474-9726.2012.00848.x","article-title":"Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N-methyl-D-aspartate receptor in mature hippocampal cultures treated with amyloid-\u03b2 oligomers","volume":"11","author":"Costa","year":"2012","journal-title":"Aging Cell"},{"key":"10.3233\/JAD-240146_ref8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.20517\/and.2023.16","article-title":"Amyloid-\u03b2-targeted therapies for Alzheimer\u2019s disease: Currently and in the future","volume":"3","author":"Huimin","year":"2023","journal-title":"Ageing Neurodegener Dis"},{"key":"10.3233\/JAD-240146_ref9","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mold Psychiatry"},{"key":"10.3233\/JAD-240146_ref10","doi-asserted-by":"crossref","first-page":"e3001694","DOI":"10.1371\/journal.pbio.3001694","article-title":"If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?","volume":"20","author":"Haass","year":"2022","journal-title":"PLoS Biol"},{"key":"10.3233\/JAD-240146_ref11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.3233\/JAD-240146_ref12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/med.21434","article-title":"Drugs in clinical trials for Alzheimer\u2019s disease: The major trends","volume":"37","author":"Bachurin","year":"2017","journal-title":"Med Res Rev"},{"key":"10.3233\/JAD-240146_ref13","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10072-016-2625-7","article-title":"Current pharmacotherapy and putative disease-modifying therapy for Alzheimer\u2019s disease","volume":"37","author":"Kulshreshtha","year":"2016","journal-title":"Neurol Sci"},{"key":"10.3233\/JAD-240146_ref14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240146_ref15","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240146_ref16","doi-asserted-by":"crossref","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","article-title":"Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease","volume":"5","author":"Jonaitis","year":"2023","journal-title":"Brain Commun"},{"key":"10.3233\/JAD-240146_ref17","first-page":"109","article-title":"Defining disease modifying therapy for Alzheimer\u2019s disease","volume":"4","author":"Cummings","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-240146_ref18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: Enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-240146_ref19","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/13543776.2021.1917549","article-title":"A patent review of glutaminyl cyclase inhibitors (2004-present)","volume":"31","author":"Coimbra","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.3233\/JAD-240146_ref20","doi-asserted-by":"crossref","first-page":"103644","DOI":"10.1016\/j.drudis.2023.103644","article-title":"Therapeutic potential of glutaminyl cyclases: Current status and emerging trends","volume":"28","author":"Coimbra","year":"2023","journal-title":"Drug Discovery Today"},{"key":"10.3233\/JAD-240146_ref21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.celrep.2017.06.023","article-title":"Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer\u2019s mouse phenotypes","volume":"20","author":"Haas","year":"2017","journal-title":"Cell Rep"},{"key":"10.3233\/JAD-240146_ref22","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer\u2019s disease modification","volume":"17","author":"Izzo","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240146_ref23","doi-asserted-by":"crossref","first-page":"eabi8593","DOI":"10.1126\/scitranslmed.abi8593","article-title":"Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q","volume":"14","author":"Spurrier","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-240146_ref24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-023-00358-w","article-title":"A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer\u2019s disease using an indwelling CSF catheter","volume":"12","author":"LaBarbera","year":"2023","journal-title":"Transl Neurodegener"},{"key":"10.3233\/JAD-240146_ref25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: Current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-240146_ref26","doi-asserted-by":"crossref","first-page":"101496","DOI":"10.1016\/j.arr.2021.101496","article-title":"Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer\u2019s disease: A systematic review","volume":"72","author":"Jeremic","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-240146_ref27","doi-asserted-by":"crossref","first-page":"e12295","DOI":"10.1002\/trc2.12295","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240146_ref28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s00415-021-10790-5","article-title":"Alzheimer\u2019s disease clinical trial update 2019\u20132021","volume":"269","author":"Pleen","year":"2022","journal-title":"J Neurol"},{"key":"10.3233\/JAD-240146_ref29","doi-asserted-by":"crossref","first-page":"e12073","DOI":"10.1002\/trc2.12073","article-title":"Advancing combination therapy for Alzheimer\u2019s disease","volume":"6","author":"Salloway","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240146_ref30","doi-asserted-by":"crossref","first-page":"e12385","DOI":"10.1002\/trc2.12385","article-title":"Alzheimer\u2019s disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240146_ref31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-secretase BACE1 in Alzheimer\u2019s disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol Psychiatry"},{"key":"10.3233\/JAD-240146_ref32","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/archneur.59.9.1381","article-title":"Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease","volume":"59","author":"Fukumoto","year":"2002","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-240146_ref33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0002-9440(10)63159-8","article-title":"Beta-secretase activity increases with aging in human, monkey, and mouse brain","volume":"164","author":"Fukumoto","year":"2004","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-240146_ref34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nm0103-3","article-title":"Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease","volume":"9","author":"Yang","year":"2003","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240146_ref35","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1073\/pnas.0205689101","article-title":"Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer\u2019s disease patients","volume":"101","author":"Li","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-240146_ref36","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1523\/JNEUROSCI.4396-06.2007","article-title":"Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer\u2019s disease pathogenesis","volume":"27","author":"Zhao","year":"2007","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240146_ref37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-016-1558-9","article-title":"Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Abeta generation in Alzheimer\u2019s disease","volume":"132","author":"Sadleir","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-240146_ref38","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1039\/C3CS60460H","article-title":"BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer\u2019s disease","volume":"43","author":"Ghosh","year":"2014","journal-title":"Chem Soc Rev"},{"key":"10.3233\/JAD-240146_ref39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/713609213","article-title":"Aspartic peptidase inhibitors: Implications in drug development","volume":"38","author":"Dash","year":"2003","journal-title":"Crit Rev Biochem Mol"},{"key":"10.3233\/JAD-240146_ref40","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.bmcl.2014.03.025","article-title":"The evolution of amidine-based brain penetrant BACE1 inhibitors","volume":"24","author":"Oehlrich","year":"2014","journal-title":"Bioorganic Med Chem Lett"},{"key":"10.3233\/JAD-240146_ref41","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1055\/a-1019-9819","article-title":"Natural compounds with anti-BACE1 activity as promising therapeutic drugs for treating Alzheimer\u2019s disease","volume":"85","author":"Naushad","year":"2019","journal-title":"Planta Med"},{"key":"10.3233\/JAD-240146_ref42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/md19060343","article-title":"Bridging cyanobacteria to neurodegenerative diseases: A new potential source of bioactive compounds against Alzheimer\u2019s disease","volume":"19","author":"Castaneda","year":"2021","journal-title":"Mar Drugs"},{"key":"10.3233\/JAD-240146_ref43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/acs.jmedchem.7b00393","article-title":"BACE-1 inhibitors: From recent single-target molecules to multitarget compounds for Alzheimer\u2019s disease","volume":"61","author":"Prati","year":"2018","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref44","doi-asserted-by":"crossref","first-page":"103649","DOI":"10.1016\/j.bioorg.2020.103649","article-title":"Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands","volume":"97","author":"Iraji","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.3233\/JAD-240146_ref46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fphys.2012.00008","article-title":"The membrane-bound aspartyl protease BACE1: Molecular and functional properties in Alzheimer\u2019s disease and beyond","volume":"3","author":"Dislich","year":"2012","journal-title":"Front Physiol"},{"key":"10.3233\/JAD-240146_ref47","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jshs.2016.10.004","article-title":"BACE1 inhibition as a therapeutic strategy for Alzheimer\u2019s disease","volume":"5","author":"Vassar","year":"2016","journal-title":"J Sport Health Sci"},{"key":"10.3233\/JAD-240146_ref48","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1021\/acs.jmedchem.9b00309","article-title":"Structure-based design of selective \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: Targeting the flap to gain selectivity over BACE2","volume":"62","author":"Fujimoto","year":"2019","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref49","doi-asserted-by":"crossref","first-page":"14175","DOI":"10.1021\/acs.jmedchem.1c00935","article-title":"JNJ-67569762, a 2-aminotetrahydropyridine-based selective BACE1 inhibitor targeting the S3 pocket: From discovery to clinical candidate","volume":"64","author":"Rombouts","year":"2021","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref50","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1021\/acs.jmedchem.8b00246","article-title":"Design and synthesis of clinical candidate PF-06751979: A potent, brain penetrant, \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor lacking hypopigmentation","volume":"61","author":"O\u2019Neill","year":"2018","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref51","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1039\/C7MD00106A","article-title":"Development of 2-aminooxazoline 3-azaxanthene \u03b2-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D","volume":"8","author":"Low","year":"2017","journal-title":"MedChemComm"},{"key":"10.3233\/JAD-240146_ref52","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1021\/jm400225m","article-title":"Beta-secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer\u2019s disease","volume":"56","author":"Hilpert","year":"2013","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fchem.2018.00178","article-title":"Highlights in BACE1 inhibitors for Alzheimer\u2019s disease treatment","volume":"6","author":"Coimbra","year":"2018","journal-title":"Front Chem"},{"key":"10.3233\/JAD-240146_ref54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13543776.2021.1832463","article-title":"Small-molecule BACE1 inhibitors: A patent literature review (2011 to 2020)","volume":"31","author":"Rombouts","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.3233\/JAD-240146_ref55","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.3390\/molecules27248823","article-title":"BACE1 inhibitors for Alzheimer\u2019s disease: The past, present and any future?","volume":"27","author":"Bazzari","year":"2022","journal-title":"Molecules"},{"key":"10.3233\/JAD-240146_ref56","doi-asserted-by":"crossref","first-page":"117047","DOI":"10.1016\/j.bmc.2022.117047","article-title":"Guanidine-based \u03b2 amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer\u2019s disease (AD): A review","volume":"74","author":"Gehlot","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.3233\/JAD-240146_ref57","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1021\/acs.jmedchem.5b00191","article-title":"Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors","volume":"58","author":"Brodney","year":"2015","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref58","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1021\/acs.jmedchem.7b01716","article-title":"Toward \u03b2-secretase-1 inhibitors with improved isoform selectivity","volume":"61","author":"Johansson","year":"2018","journal-title":"J Med Chem."},{"key":"10.3233\/JAD-240146_ref59","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1021\/acs.jmedchem.0c02143","article-title":"Synthesis of the potent, selective, and efficacious \u03b2-secretase (BACE1) inhibitor NB-360","volume":"64","author":"Rueeger","year":"2021","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref60","doi-asserted-by":"crossref","first-page":"e9316","DOI":"10.15252\/emmm.201809316","article-title":"The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer\u2019s disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-240146_ref61","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1021\/acs.jmedchem.1c01300","article-title":"Discovery of Umibecestat (CNP520): A potent, selective, and efficacious \u03b2-secretase (BACE1) inhibitor for the prevention of Alzheimer\u2019s disease","volume":"64","author":"Machauer","year":"2021","journal-title":"J Med Chem."},{"key":"10.3233\/JAD-240146_ref62","unstructured":"Alzforum, Therapeutics - Umibecestat, https:\/\/www.alzforum.org\/therapeutics\/umibecestat, Accessed 18 March 2024."},{"key":"10.3233\/JAD-240146_ref63","doi-asserted-by":"crossref","first-page":"11621","DOI":"10.1523\/JNEUROSCI.1405-14.2014","article-title":"Combined treatment with a BACE inhibitor and anti-A\u03b2 antibody gantenerumab enhances amyloid reduction in APPLondon mice","volume":"34","author":"Jacobsen","year":"2014","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240146_ref64","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.1021\/acs.jmedchem.9b01140","article-title":"Discovery of an extremely potent thiazine-based \u03b2-secretase inhibitor with reduced cardiovascular and liver toxicity at a low projected human dose","volume":"62","author":"Tadano","year":"2019","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref65","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1021\/acs.jmedchem.9b01034","article-title":"Discovery of AM-6494: A potent and orally efficacious \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with in vivo selectivity over BACE2","volume":"63","author":"Pettus","year":"2020","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref66","doi-asserted-by":"crossref","first-page":"14165","DOI":"10.1021\/acs.jmedchem.1c00359","article-title":"Discovery of extremely selective fused pyridine-derived \u03b2-site amyloid precursor protein-cleaving enzyme (BACE1) inhibitors with high in vivo efficacy through 10s loop interactions","volume":"64","author":"Ueno","year":"2021","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref67","doi-asserted-by":"crossref","first-page":"16507","DOI":"10.1523\/JNEUROSCI.3647-11.2011","article-title":"Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor","volume":"31","author":"May","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240146_ref68","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","article-title":"The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans","volume":"35","author":"May","year":"2015","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240146_ref69","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1021\/acs.jmedchem.1c00489","article-title":"Discovery and early clinical development of LY3202626, a low-dose, CNS-penetrant BACE inhibitor","volume":"64","author":"McKinzie","year":"2021","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref70","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1021\/acs.jmedchem.0c01917","article-title":"Discovery of Atabecestat (JNJ-54861911): A thiazine-based \u03b2-amyloid precursor protein cleaving enzyme 1 inhibitor advanced to the phase 2b\/3 EARLY clinical trial","volume":"64","author":"Koriyama","year":"2021","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/ADR-210037","article-title":"Robust pharmacodynamic effect of LY3202626, a central nervous system penetrant, low dose BACE1 inhibitor, in humans and nonclinical species","volume":"6","author":"Willis","year":"2022","journal-title":"J Alzheimers Dis Rep"},{"key":"10.3233\/JAD-240146_ref72","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/ADR-210296","article-title":"Phase II (NAVIGATE-AD study) results of LY3202626 effects on patients with mild Alzheimer\u2019s disease dementia","volume":"5","author":"Lo","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"key":"10.3233\/JAD-240146_ref73","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: A truncated randomized phase 2b\/3 clinical trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240146_ref74","unstructured":"Alzforum, Therapeutics - Elenbecestat, https:\/\/www.alzforum.org\/therapeutics\/elenbecestat, Accessed 29 December 2023."},{"key":"10.3233\/JAD-240146_ref75","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3233\/JAD-190228","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of PF-06751979, a potent and selective oral BACE1 inhibitor: Results from phase I studies in healthy adults and healthy older subjects","volume":"71","author":"Qiu","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240146_ref76","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1021\/acs.jmedchem.6b00307","article-title":"Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-Abeta-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer\u2019s disease","volume":"59","author":"Scott","year":"2016","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref77","doi-asserted-by":"crossref","first-page":"128463","DOI":"10.1016\/j.bmcl.2021.128463","article-title":"Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors","volume":"56","author":"Taoka","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.3233\/JAD-240146_ref78","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/cts.12645","article-title":"Safety, tolerability, and pharmacokinetics of the \u03b2-site amyloid precursor protein-cleaving enzyme 1 inhibitor verubecestat (MK-8931) in healthy elderly male and female subjects","volume":"12","author":"Forman","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.3233\/JAD-240146_ref79","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240146_ref80","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3233\/JAD-150834","article-title":"AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics","volume":"50","author":"Eketjall","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240146_ref81","doi-asserted-by":"crossref","first-page":"41245","DOI":"10.1074\/jbc.M112.409110","article-title":"Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease","volume":"287","author":"Jeppsson","year":"2012","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-240146_ref82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240146_ref83","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/alz.12164","article-title":"Cognitive outcomes in trials of two BACE inhibitors in Alzheimer\u2019s disease","volume":"16","author":"Wessels","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240146_ref84","doi-asserted-by":"crossref","first-page":"e12123","DOI":"10.1002\/trc2.12123","article-title":"Lanabecestat: Neuroimaging results in early symptomatic Alzheimer\u2019s disease","volume":"7","author":"Zimmer","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240146_ref85","doi-asserted-by":"crossref","first-page":"126772","DOI":"10.1016\/j.bmcl.2019.126772","article-title":"Design, synthesis and evaluation of 2-amino-imidazol-4-one derivatives as potent \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE-1) inhibitors","volume":"29","author":"Fan","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.3233\/JAD-240146_ref86","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ddr.21585","article-title":"Design, synthesis, and biological activity evaluation of BACE1 inhibitors with antioxidant activity","volume":"81","author":"Li","year":"2020","journal-title":"Drug Dev Res"},{"key":"10.3233\/JAD-240146_ref87","doi-asserted-by":"crossref","first-page":"114028","DOI":"10.1016\/j.ejmech.2021.114028","article-title":"Modulating physicochemical properties of tetrahydropyridine-2-amine BACE1 inhibitors with electron-withdrawing groups: A systematic study","volume":"228","author":"Rombouts","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-240146_ref88","doi-asserted-by":"crossref","first-page":"113270","DOI":"10.1016\/j.ejmech.2021.113270","article-title":"Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central A\u03b2 reduction","volume":"216","author":"Nakahara","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-240146_ref89","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1021\/acsmedchemlett.9b00181","article-title":"Evaluation of a series of \u03b2-secretase 1 inhibitors containing novel heteroaryl-fused-piperazine amidine warheads","volume":"10","author":"Oehlrich","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.3233\/JAD-240146_ref90","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1021\/acsmedchemlett.1c00445","article-title":"A brain-penetrant and bioavailable pyrazolopiperazine BACE1 inhibitor elicits sustained reduction of amyloid \u03b2 in vivo","volume":"13","author":"Peschiulli","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.3233\/JAD-240146_ref91","doi-asserted-by":"crossref","first-page":"103135","DOI":"10.1016\/j.bioorg.2019.103135","article-title":"4-Substituted 2-amino-3,4-dihydroquinazolines with a 3-hairpin turn side chain as novel inhibitors of BACE-1","volume":"95","author":"Jagtap","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.3233\/JAD-240146_ref92","doi-asserted-by":"crossref","first-page":"128543","DOI":"10.1016\/j.bmcl.2022.128543","article-title":"Synthesis, radiolabeling, and evaluation of a potent \u03b2-site APP cleaving enzyme (BACE1) inhibitor for PET imaging of BACE1 in vivo","volume":"59","author":"Pan","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.3233\/JAD-240146_ref93","doi-asserted-by":"crossref","first-page":"102033","DOI":"10.1016\/j.arr.2023.102033","article-title":"The neurobiology and therapeutic potential of multi-targeting \u03b2-secretase, glycogen synthase kinase 3\u03b2 and acetylcholinesterase in Alzheimer\u2019s disease","volume":"90","author":"Fronza","year":"2023","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-240146_ref94","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41582-021-00545-1","article-title":"The case for low-level BACE1 inhibition for the prevention of Alzheimer disease","volume":"17","author":"McDade","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-240146_ref95","doi-asserted-by":"crossref","first-page":"e041140","DOI":"10.1002\/alz.041140","article-title":"Umibecestat in the API Generation program: Worsening in RBANS and\/or CDR on treatment reverses after wash-out","volume":"16","author":"Graf","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240146_ref96","doi-asserted-by":"crossref","first-page":"e041142","DOI":"10.1002\/alz.041142","article-title":"The API Generation program: Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloid-negative APOE4 homozygotes","volume":"16","author":"Reiman","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240146_ref97","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3233\/JAD-200381","article-title":"New BACE1 chimeric peptide inhibitors selectively prevent A\u03b2PP-\u03b2 cleavage decreasing amyloid-\u03b2 production and accumulation in Alzheimer\u2019s disease models","volume":"76","author":"Resende","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240146_ref98","doi-asserted-by":"crossref","first-page":"26326","DOI":"10.1074\/jbc.M611687200","article-title":"Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice","volume":"282","author":"McConlogue","year":"2007","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-240146_ref99","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1084\/jem.20171831","article-title":"BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions","volume":"215","author":"Hu","year":"2018","journal-title":"J Exp Med"},{"key":"10.3233\/JAD-240146_ref100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"10.3233\/JAD-240146_ref101","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ana.24969","article-title":"Decreased plasma \u03b2-amyloid in the Alzheimer\u2019s disease APP A673T variant carriers","volume":"82","author":"Martiskainen","year":"2017","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-240146_ref102","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","article-title":"Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: A longitudinal study","volume":"17","author":"Gordon","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240146_ref103","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JAD-240146_ref104","doi-asserted-by":"crossref","first-page":"101792","DOI":"10.1016\/j.jbc.2022.101792","article-title":"Verteporfin is a substrate-selective \u03b3-secretase inhibitor that binds the amyloid precursor protein transmembrane domain","volume":"298","author":"Castro","year":"2022","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-240146_ref105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41380-018-0101-x","article-title":"A presenilin-1 mutation causes Alzheimer disease without affecting Notch signaling","volume":"25","author":"Zhang","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-240146_ref106","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tins.2016.01.003","article-title":"BACE1 physiological functions may limit its use as therapeutic target for Alzheimer\u2019s disease","volume":"39","author":"Bar\u00e3o","year":"2016","journal-title":"Trends Neurosci"},{"key":"10.3233\/JAD-240146_ref107","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.3233\/JAD-220867","article-title":"BACE2: A promising neuroprotective candidate for Alzheimer\u2019s disease","volume":"94","author":"Yeap","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240146_ref108","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1038\/s41380-020-0806-5","article-title":"Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain","volume":"26","author":"Ali\u0107","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-240146_ref109","doi-asserted-by":"crossref","first-page":"9640","DOI":"10.1038\/s41598-019-45896-4","article-title":"Common BACE2 polymorphisms are associated with altered risk for Alzheimer\u2019s disease and CSF amyloid biomarkers in APOE \u025b4 non-carriers","volume":"9","author":"Huentelman","year":"2019","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-240146_ref110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2005.04.008","article-title":"Chromosome 21 BACE2 haplotype associates with Alzheimer\u2019s disease: A two-stage study","volume":"236","author":"Myllykangas","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-240146_ref111","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1750-1326-7-46","article-title":"Identification of BACE2 as an avid \u00df-amyloid-degrading protease","volume":"7","author":"Abdul-Hay","year":"2012","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-240146_ref112","doi-asserted-by":"crossref","first-page":"e13430","DOI":"10.1111\/obr.13430","article-title":"BACE1: More than just a \u03b2-secretase","volume":"23","author":"Taylor","year":"2022","journal-title":"Obes Rev"},{"key":"10.3233\/JAD-240146_ref113","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","article-title":"A close look at BACE1 inhibitors for Alzheimer\u2019s disease treatment","volume":"33","author":"Das","year":"2019","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-240146_ref114","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1038\/s41380-021-01166-2","article-title":"BACE1 controls synaptic function through modulating release of synaptic vesicles","volume":"26","author":"Das","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-240146_ref115","doi-asserted-by":"crossref","first-page":"eaao5620","DOI":"10.1126\/scitranslmed.aao5620","article-title":"Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice","volume":"10","author":"Ou-Yang","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-240146_ref116","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fnmol.2017.00097","article-title":"Physiological functions of the beta-site amyloid precursor protein cleaving enzyme 1 and 2","volume":"10","author":"Yan","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JAD-240146_ref117","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.celrep.2016.01.076","article-title":"Specific inhibition of beta-secretase processing of the Alzheimer disease amyloid precursor protein","volume":"14","author":"Ben Halima","year":"2016","journal-title":"Cell Rep"},{"key":"10.3233\/JAD-240146_ref118","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nn.4188","article-title":"Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway","volume":"19","author":"Das","year":"2016","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-240146_ref119","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fnagi.2018.00118","article-title":"The physiological roles of amyloid-\u03b2 peptide hint at new ways to treat Alzheimer\u2019s disease","volume":"10","author":"Brothers","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240146_ref120","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1126\/science.abp9556","article-title":"MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer\u2019s disease","volume":"381","author":"Balusu","year":"2023","journal-title":"Science"},{"key":"10.3233\/JAD-240146_ref121","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab \u2014 binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-240146_ref122","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s13311-023-01405-0","article-title":"Anti-amyloid immunotherapies for Alzheimer\u2019s disease: A 2023 clinical update","volume":"20","author":"Yadollahikhales","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-240146_ref124","doi-asserted-by":"crossref","first-page":"e069220","DOI":"10.1002\/alz.069220","article-title":"Neuropathological autopsy findings in an individual with Alzheimer\u2019s disease who received long-term treatment with lecanemab (BAN2401)","volume":"18","author":"Honig","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240146_ref125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240146_ref126","first-page":"771","article-title":"Lecanemab Clarity AD: Quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer\u2019s disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-240146_ref127","first-page":"362","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-240146_ref128","unstructured":"EMA, Aduhelm: Withdrawal of the marketing authorisation application, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/aduhelm, Accessed 10 December 2023."},{"key":"10.3233\/JAD-240146_ref129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41582-020-00454-9","article-title":"Aducanumab and the FDA - where are we now?","volume":"17","author":"Fillit","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-240146_ref130","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.3233\/JAD-240146_ref131","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: A secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240146_ref132","unstructured":"Eli Lilly and Company, Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer\u2019s Disease, https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-shares-positive-donanemab-data-first-active-comparator, Accessed 10 December 2023."},{"key":"10.3233\/JAD-240146_ref133","doi-asserted-by":"crossref","first-page":"105365","DOI":"10.1016\/j.nbd.2021.105365","article-title":"Passive immunotherapy with a novel antibody against 3pE-modified A\u03b2 demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice","volume":"154","author":"Janssens","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-240146_ref134","first-page":"398","article-title":"Aducanumab: Appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-240146_ref135","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti\u2013 \u03b2-amyloid drugs","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"10.3233\/JAD-240146_ref136","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-022-01273-8","article-title":"Fc effector of anti-A\u03b2 antibody induces synapse loss and cognitive deficits in Alzheimer\u2019s disease-like mouse model","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.3233\/JAD-240146_ref137","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240146_ref138","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1093\/brain\/awz268","article-title":"The bivariate distribution of amyloid-\u03b2 and tau: Relationship with established neurocognitive clinical syndromes","volume":"142","author":"Jack","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JAD-240146_ref139","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/brain\/awad049","article-title":"An anti-amyloid therapy works for Alzheimer\u2019s disease: Why has it taken so long and what is next?","volume":"146","author":"Hardy","year":"2023","journal-title":"Brain"},{"key":"10.3233\/JAD-240146_ref140","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/brain\/awy059","article-title":"Longitudinal tau PET in ageing and Alzheimer\u2019s disease","volume":"141","author":"Jack","year":"2018","journal-title":"Brain"},{"key":"10.3233\/JAD-240146_ref141","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/00365510701864610","article-title":"Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer\u2019s disease","volume":"69","author":"Hampel","year":"2009","journal-title":"Scand J Clin Lab Invest"},{"key":"10.3233\/JAD-240146_ref142","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000489847","article-title":"Neurogranin and BACE1 in CSF as potential biomarkers differentiating depression with cognitive deficits from early Alzheimer\u2019s disease: A pilot study","volume":"8","author":"Schipke","year":"2018","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"10.3233\/JAD-240146_ref143","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.biopsych.2017.02.007","article-title":"Increased plasma beta-secretase 1 may predict conversion to Alzheimer\u2019s disease dementia in individuals with mild cognitive impairment","volume":"83","author":"Shen","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.3233\/JAD-240146_ref144","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13195-020-00686-3","article-title":"\u03b2-Secretase1 biological markers for Alzheimer\u2019s disease: State-of-art of validation and qualification","volume":"12","author":"Hampel","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240146_ref145","doi-asserted-by":"crossref","first-page":"e9712","DOI":"10.15252\/emmm.201809712","article-title":"CSF progranulin increases in the course of Alzheimer\u2019s disease and is associated with sTREM2, neurodegeneration and cognitive decline","volume":"10","author":"Su\u00e1rez-Calvet","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-240146_ref146","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/brain\/awv267","article-title":"Cerebrospinal fluid neurogran: Relation to cognition and neurodegeneration in Alzheimer\u2019s disease","volume":"138","author":"Portelius","year":"2015","journal-title":"Brain"},{"key":"10.3233\/JAD-240146_ref147","unstructured":"Clinicaltrials.gov, Washington University School of Medicine. A phase II\/III multicenter randomized, double-blind, placebo-controlled platform trial of potential disease modifying therapies utilizing biomarker, cognitive, and clinical endpoints in dominantly inherited Alzheimer\u2019s disease, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05269394 Accessed 7 January 2024."},{"key":"10.3233\/JAD-240146_ref148","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1021\/acschemneuro.3c00245","article-title":"Design, synthesis, and biological evaluation of piperazine and N-benzylpiperidine hybrids of 5-phenyl-1,3,4-oxadiazol-2-thiol as potential multitargeted ligands for Alzheimer\u2019s disease therapy","volume":"14","author":"Waiker","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JAD-240146_ref149","doi-asserted-by":"crossref","first-page":"106749","DOI":"10.1016\/j.bioorg.2023.106749","article-title":"Design and development of benzyl piperazine linked 5-phenyl-1,2,4-triazole-3-thione conjugates as potential agents to combat Alzheimer\u2019s disease","volume":"139","author":"Kiran","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.3233\/JAD-240146_ref150","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1021\/acschemneuro.3c00030","article-title":"Design, synthesis, and pharmacological evaluation of embelin\u2013Aryl\/alkyl amine hybrids as orally bioavailable blood\u2013 brain barrier permeable multitargeted agents with therapeutic potential in Alzheimer\u2019s disease: Discovery of SB-1448","volume":"14","author":"Nuthakki","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JAD-240146_ref151","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejmech.2019.02.030","article-title":"Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer\u2019s disease","volume":"167","author":"Sharma","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-240146_ref152","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1021\/acs.jmedchem.5b00894","article-title":"Versatility of the curcumin scaffold: Discovery of potent and balanced dual BACE-1 and GSK-3\u03b2 inhibitors","volume":"59","author":"Di Martino","year":"2016","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240146_ref153","doi-asserted-by":"crossref","first-page":"32131","DOI":"10.1021\/acsomega.2c03368","article-title":"Design, synthesis, and biological evaluation of notopterol derivatives as triple inhibitors of AChE\/BACE1\/GSK3\u03b2 for the treatment of Alzheimer\u2019s disease","volume":"7","author":"Wang","year":"2022","journal-title":"ACS Omega"},{"key":"10.3233\/JAD-240146_ref154","doi-asserted-by":"crossref","first-page":"114689","DOI":"10.1016\/j.ejmech.2022.114689","article-title":"Design, synthesis and biological evaluation of novel coumarin derivatives as multifunctional ligands for the treatment of Alzheimer\u2019s disease","volume":"242","author":"Liu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-240146_ref155","doi-asserted-by":"crossref","first-page":"108529","DOI":"10.1016\/j.steroids.2019.108529","article-title":"Sarsasapogen: A steroidal saonin from Asparagus racemosus as multi target directed ligand in Alzheimer\u2019s disease","volume":"153","author":"Kashyap","year":"2020","journal-title":"Steroids"},{"key":"10.3233\/JAD-240146_ref156","doi-asserted-by":"crossref","first-page":"115832","DOI":"10.1016\/j.ejmech.2023.115832","article-title":"Discovery of novel multifunctional ligands targeting GABA transporters, butyrylcholinesterase, \u03b2-secretase, and amyloid \u03b2 aggregation as potential treatment of Alzheimer\u2019s disease","volume":"261","author":"Zar\u0119ba","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-240146_ref157","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3390\/biom9110736","article-title":"Exploring biological activity of 4-Oxo-4H-furo[2,3-h]chromene derivatives as potential multi-target-directed ligands inhibiting cholinesterases, \u03b2-secretase, cyclooxygenase-2, and lipoxygenase-5\/15","volume":"9","author":"Mphahlele","year":"2019","journal-title":"Biomolecules"},{"key":"10.3233\/JAD-240146_ref158","doi-asserted-by":"crossref","first-page":"113441","DOI":"10.1016\/j.ejmech.2021.113441","article-title":"Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer\u2019s disease","volume":"219","author":"Qu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-240146_ref159","doi-asserted-by":"crossref","first-page":"117535","DOI":"10.1016\/j.bmc.2023.117535","article-title":"Multifunctional agents against Alzheimer\u2019s disease based on oxidative stress: Polysubstituted pyrazine derivatives synthesized by multicomponent reactions","volume":"96","author":"Wei","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.3233\/JAD-240146_ref160","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","article-title":"Aducanumab: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.3233\/JAD-240146_ref161","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240146_ref162","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240146_ref163","unstructured":"neurologylive, Eli Lilly\u2019s Remternetug Demonstrates Significant Amyloid Plaque Removal in Early-Stage Trial, https:\/\/www.neurologylive.com\/view\/eli-lilly-remternetug-demonstrates-significant-amyloid-plaque-removal-early-stage-trial, Accessed 09 December 2023."},{"key":"10.3233\/JAD-240146_ref164","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer\u2019s disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240146_ref165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: An anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240146_ref166","doi-asserted-by":"crossref","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttletrademark amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"mAbs"},{"key":"10.3233\/JAD-240146_ref167","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: Two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240146_ref168","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-240146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:59:18Z","timestamp":1777370358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/JAD-240146"}},"subtitle":[],"editor":[{"given":"Paula I.","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"Jesus","family":"Avila","sequence":"additional","affiliation":[]},{"given":"Daniela","family":"Galimberti","sequence":"additional","affiliation":[]},{"given":"Miguel A.","family":"Pappolla","sequence":"additional","affiliation":[]},{"given":"Germ\u00e1n","family":"Plascencia-Villa","sequence":"additional","affiliation":[]},{"given":"Aaron A.","family":"Sorensen","sequence":"additional","affiliation":[]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":166,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-240146","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}